The oral agent ozanimod continues to demonstrate benefit against ulcerative colitis, according to two studies presented at the 2022 meeting of the European Crohn’s and Colitis Organisation.
The new research shows that ozanimod (Zeposia, Bristol Myers Squibb) can provide long-term, sustained disease response and points to the possibility of use as a second-line therapy.
In one of the two studies, a proportion of patients with moderate to severely active UC continued to report a clinical